Company Overview
| Stock Name | Simcere Pharma |
|---|---|
| Stock Code | 02096 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家從事藥品研發、生產和商業化的公司,目前主要從事仿製藥業務,專注腫瘤疾病、中樞神經系統疾病及自身免疫疾病等治療領域。 |
| Listing Date | 2020-10-27 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 江蘇省南京市玄武區玄武大道699-18號 |
| Business Address (Hong Kong) | 香港北角電氣道183號友邦廣場43樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | simcere.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 13.70 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 13,700 |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | 260,569,000 shares |
| HK Public Offer Shares (Initial) | 26,058,000 shares (10.0%) |
| Public Offer Lots (Initial) | 26,058lots (Pool A13,029lots,Pool B13,029lots) |
| International Placing Shares (Initial) | 234,511,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 2,605,686,618 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 41.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,569,795,300 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 13,700 |
| 2 lots | 2,000 | HK$ 27,400 |
| 3 lots | 3,000 | HK$ 41,100 |
| 4 lots | 4,000 | HK$ 54,800 |
| 5 lots | 5,000 | HK$ 68,500 |
| 6 lots | 6,000 | HK$ 82,200 |
| 7 lots | 7,000 | HK$ 95,900 |
| 8 lots | 8,000 | HK$ 109,600 |
| 9 lots | 9,000 | HK$ 123,300 |
| 10 lots | 10,000 | HK$ 137,000 |
| 15 lots | 15,000 | HK$ 205,500 |
| 20 lots | 20,000 | HK$ 274,000 |
| 25 lots | 25,000 | HK$ 342,500 |
| 30 lots | 30,000 | HK$ 411,000 |
| 35 lots | 35,000 | HK$ 479,500 |
| 40 lots | 40,000 | HK$ 548,000 |
| 45 lots | 45,000 | HK$ 616,500 |
| 50 lots | 50,000 | HK$ 685,000 |
| 60 lots | 60,000 | HK$ 822,000 |
| 70 lots | 70,000 | HK$ 959,000 |
| 80 lots | 80,000 | HK$ 1,096,000 |
| 90 lots | 90,000 | HK$ 1,233,000 |
| 100 lots | 100,000 | HK$ 1,370,000 |
| 200 lots | 200,000 | HK$ 2,740,000 |
| 300 lots | 300,000 | HK$ 4,110,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 400,000 | HK$ 5,480,000 |
| 500 lots | 500,000 | HK$ 6,850,000 |
| 600 lots | 600,000 | HK$ 8,220,000 |
| 700 lots | 700,000 | HK$ 9,590,000 |
| 800 lots | 800,000 | HK$ 10,960,000 |
| 900 lots | 900,000 | HK$ 12,330,000 |
| 1,000 lots | 1,000,000 | HK$ 13,700,000 |
| 2,000 lots | 2,000,000 | HK$ 27,400,000 |
| 3,000 lots | 3,000,000 | HK$ 41,100,000 |
| 4,000 lots | 4,000,000 | HK$ 54,800,000 |
| 5,000 lots | 5,000,000 | HK$ 68,500,000 |
| 6,000 lots | 6,000,000 | HK$ 82,200,000 |
| 7,000 lots | 7,000,000 | HK$ 95,900,000 |
| 8,000 lots | 8,000,000 | HK$ 109,600,000 |
| 9,000 lots | 9,000,000 | HK$ 123,300,000 |
| 10,000 lots | 10,000,000 | HK$ 137,000,000 |
| 13,029 lots | 13,029,000 | HK$ 178,497,300 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 29.41B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 35,697,906,666 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 2019年盈利約人民幣1,003.6百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 10.98 |
|---|---|
| First Day Open | HK$ 11.0 |
| First Day Change | -19.85% |
| First Day Volume | 125444000.0 |
| First Day Turnover | 1369320000.0 |
| Use of Proceeds | 1、約60%(或2,035.4百萬港元)將分配予我們在戰略重點治療領域中選定的在研產品的持續研發;
2、約10%(或339.2百萬港元)將分配予加強我們的銷售及營銷能力;
3、約10%(或339.2百萬港元)將分配予我們于未來幾年投資醫藥或生物技術領域的公司,以拓寬我們的產品組合;
4、約10%(或339.2百萬港元)將分配予償還如下表所示的若干未償還銀行貸款;
5、約10%(或339.2百萬港元)將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (4)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Hillhouse Funds | 387,504,500 HKD | — | 10.86% | — | 6 months | 2021-04-27 |
| 2 | Jericho Capital Master Fund L.P. | 77,500,900 HKD | — | 2.17% | — | 6 months | 2021-04-27 |
| 3 | Lake Bleu Prime Healthcare Master Fund Limited | 193,745,400 HKD | — | 5.43% | — | 6 months | 2021-04-27 |
| 4 | OrbiMed Funds | 193,745,400 HKD | — | 5.43% | — | 6 months | 2021-04-27 |
| 5 | Sage Partners Master Fund | 77,500,900 HKD | — | 2.17% | — | 6 months | 2021-04-27 |
| 6 | 高新(香港)有限公司 | 310,003,600 HKD | — | 8.68% | — | 6 months | 2021-04-27 |
| 7 | 红土创新国际有限公司 | 232,489,000 HKD | — | 6.51% | — | 6 months | 2021-04-27 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 任晉生 | — |
| Company Secretary | 鮑軍、馮潔、麥寶文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東任晉生先生及其一致行動人士(包括任用先生、李詩濛女士、任衛東先生、任真女士、彭素琴女士等)合共持有2,035,922,965股股份,緊隨全球發售完成後佔已發行股本約78.13%。 |
|---|




